Introduction
Fundamental differences between tumor and normal vasculature present unique targets for anti-cancer therapy (Siemann, 2011) , and there is a need to identify and further characterize these. A major cause of these differences is the influence of the extracellular environment on the endothelial transcriptome. Endothelial cells resident within a tumor are exposed to an extracellular environment markedly different from that of endothelial cells resident in healthy tissue. For example, an endothelial cell within a tumor microenvironment will experience hypoxia that alone can change the expression of up to 2000 genes (Dachs and Chaplin, 1998) . Tumors also show nutrient (for example, glucose) deprivation, acidic extracellular pH, high interstitial pressure (Helmlinger et al., 1997) , excess of pro-angiogenic activity (for example, vascular endothelial (VE) growth factor) and increased mechanical compression (Padera et al., 2004) . Each of these factors may influence the transcriptome.
Differential gene expression analysis can be used to identify targets lying within the vasculature. Targeting can then be achieved with antibodies, antibody conjugates or more recently vaccines (reviewed in Heath and Bicknell, 2009; Chinnasamy et al., 2010; Huijbers et al., 2010) . Nevertheless, despite success in targeting the tumor vasculature in animal models (Burrows and Thorpe, 1993; Huang et al., 1997; He et al., 2009) , the translation of vascular targeting agents to the clinic has been slow, owing to some extent to the absence of a rigorously characterized tumor endothelial marker (TEM) in man. The success of antibody and vaccine approaches will be reflected by the specificity of the target for tumor endothelium, and this has prompted the search for well-defined TEMs. Attempts to identify TEMs have used serial analysis of gene expression (SAGE) libraries constructed from freshly isolated endothelium (St Croix et al., 2000) , a microarray platform (Ho et al., 2003) and proteomic analysis of freshly harvested endothelial cell membranes (Oh et al., 2004) , as well as bioinformatics datamining (Huminiecki and Bicknell, 2000; Herbert et al., 2008) . These studies have identified several promising TEM candidates, including the extra domain B of fibronectin, a series of numbered TEMs, annexin A and ROBO4 (Heath and Bicknell, 2009) . Unfortunately, the expression of some of these targets is not as widespread as was hoped for (Heath and Bicknell, 2009) , and there remains a need to identify novel and improved targets. In this study, we identify and characterize a novel TEM, CLEC14A, which has properties that suggest it is a candidate for tumor vascular targeting and anti-angiogenic approaches.
Results
CLEC14A is an endothelial-specific C-type lectin Bioinformatics data mining predicted that CLEC14A is an endothelial-specific gene. Real-time PCR analysis of CLEC14A showed high expression in endothelial cells (human umbilical vein endothelial cells (HUVEC) and human dermal microvascular endothelial cells), detectable in MRC5 (human diploid fibroblast cell line), but essentially absent in other primary cell isolates ( Figure 1a ).
Human CLEC14A (NP_778230) is a 490 amino acid, single pass type I transmembrane protein that has orthologs in other vertebrates, including fish. Amino acids 1-22 of CLEC14A code for a signal peptide. The extracellular domain (amino acids 23-398) includes a C-type lectin and a single epidermal growth factor-like domain. Finally, a small cytoplasmic tail of 69 amino acids follows the transmembrane domain comprising amino acids 399-421. The human and mouse CLEC14A proteins show 67% sequence identity and a clustal multiple sequence alignment of these orthologs revealed greater sequence conservation within the C-type lectin and epidermal growth factor domains (data not shown). CLEC14A is a member of the type 14 family of calcium dependent C-type lectins that also includes endosialin/ TEM1, thrombomodulin and CD93 (Zelensky and Gready, 2005; Figure 1b) . Bioinformatics prediction of potential glycosylation sites identified one highly conserved N-and nine poorly conserved O-glycosylation sites (data not shown).
CLEC14A is strongly expressed on tumor vasculature compared with vasculature in healthy tissue Polyclonal antiserum to the extracellular domain of CLEC14A was used to immunostain human healthy and cancer tissues. In the liver cancer, the tumor tissue can be delineated from the adjacent normal by a fibrotic capsule. In a liver section in which the hepatocellular carcinoma and adjacent normal are present on the same slide, strong CLEC14A staining was detected in the tumor but not in the normal tissue ( Figure 2a ). We then compared the expression of CLEC14A in healthy normal and tumor tissues. CLEC14A was strongly expressed on tumor vessels in prostate, breast, kidney and thyroid but absent in vessels of corresponding normal tissue (Figure 2b ). To determine whether CLEC14A is endothelial expressed in tissues, we carried out double immunofluorescence staining with CLE-C14A and the human endothelial marker Ulex lectin (Holthofer et al., 1982) . Analysis was performed on tissue arrays (10 different carcinoma types per array, matched adjacent normal tissue, 10 samples of each). Widespread expression of CLEC14A was seen in tumor vessels, but we again failed to detect CLEC14A on vessels in normal tissue (Figure 3a) . The expression profile of CLEC14A was compared with that of the previously characterized TEM, ROBO4 (Huminiecki et al., 2002; Seth et al., 2005) . Immunofluorescence analysis detected ROBO4 on vessels in many tumors but 
Cellular localization of CLEC14A in endothelial cells
Fluorescence-activated cell-sorting analysis of HUVEC showed CLEC14A to be cell surface expressed (data not shown). Immunofluorescence staining revealed co-localization of CLEC14A and VE cadherin at cell-to-cell contact regions in a confluent monolayer (Figure 4a ). In a scratch-wound assay, VE cadherin was lost from the CLEC14A is a novel tumor endothelial marker M Mura et al leading edge but not CLEC14A ( Figure 4b ). This suggests that although CLEC14A is localized at cellto-cell contacts, it may be poised to have a sensing role at the leading edge. It is well established that the Golgi apparatus orientates toward the direction of cell movement (Tomar et al., 2009) . Staining of the Golgi with the marker GM130 showed that CLEC14A polarizes to the HUVEC leading edge (Figure 4c ), providing further evidence for a role for this protein in environmental sensing and cell migration.
CLEC14A promotes filopodia formation, cell migration and tube formation
To explore the function of CLEC14A, it was ectopically expressed in human embryonic kidney 293 and HeLa cells, both of which lack endogenous CLEC14A. The CLEC14A-transfected cells showed extensive filopodia compared with empty vector-transfected controls ( Figure 5 ).
We then used small interfering RNA (siRNA) knockdown to further examine the function of CLEC14A. CLEC14A protein expression was efficiently knocked down by two independent siRNA duplexes ( Figure 6a ). CLEC14A knockdown was also confirmed by immunofluorescence staining of the HUVEC monolayer ( Figure 6b ).
Migration of HUVEC after CLEC14A knockdown was compared with that of mock and scrambled siRNAtransfected controls in a scratch-wound assay. At 24 h, control wounds were fully closed, whereas in CLEC14-knockdown cells, the wound remained 45% open (Figures 6c and d ). CLEC14A knockdown also compromised tube formation on matrigel. Thus, tubes showed a significant decrease in branching (Po0.001) compared with controls (Figures 6e and f).
Polyclonal antiserum to CLEC14A impairs HUVEC migration and tube formation The effect of CLEC14A antiserum on HUVEC migration and tube formation was examined. Compared with the fully closed controls, 14% of a scratch-wound was open at 22 h after treatment with anti-CLEC14A antiserum (10 or 20 mg/ml; Figures 7a and b). Treatment with anti-CLEC14A antiserum (5, 10 and 20 mg/ml) also impaired tube formation (Figures 7c and d) . As with siRNA knockdown of CLEC14A, a significant decrease (Po0.05) in branching was seen in the antiserum-treated cells.
CLEC14A and vascular development in zebrafish
We next sought to address the role of CLEC14A during vascular development using the zebrafish model. Reverse transcriptase (RT)-PCR analysis of RNA extracted from zebrafish embryos at different stages of development was used to document zclec14a expression. Zclec14a first appeared at 12 h post fertilization (h.p.f.) and expression increased up to 25 h.p.f. (Figure 8a ). An antisense mRNA probe for the zebrafish clec14a ortholog was used for mRNA in situ hybridization analysis of 24 h.p.f. embryos. Using zfli1a as an endothelial marker control, the analysis showed vascular-specific expression of zclec14a in the dorsal aorta, cardinal vein, intersomitic vessels of the trunk (Figure 8b ) and in vessels of the head (data not shown).
Morpholino antisense-mediated knockdown of zclec14a was carried out to probe a potential function in embryonic vascular development. A translation blocking zclec14a morpholino was injected into fli1a:enhanced green fluorescent protein-transgenic embryos at different concentrations (2-8 ng/embryo). Injection of 4 ng/embryo of zclec14a morpholino resulted in defects in both intersomitic vessels and dorsal longitudinal anastomotic vessels (Figure 8c ). This defect was rescued by co-injection of human CLEC14A mRNA with the morpholino, confirming that the vascular developmental defects are indeed due to loss of a functional CLEC14A ortholog. Injection of human CLEC14A mRNA (30 pg/ embryo) alone had no effect on the developing zebrafish vasculature.
Shear stress regulates expression of the TEMs CLEC14A and ROBO4 In the light of documented poor blood perfusion seen in tumor vasculature (Gullino, 1975; Jain, 1988; Chaplin et al., 1997) , we investigated the effect of shear stress on endothelial gene expression. Microarray analysis of HUVEC gene expression under static and 2 Pa laminar shear stress showed CLEC14A and ROBO4 were markedly upregulated (significant false discovery rate of o12% and o1% respectively) in the absence of shear stress. Real-time PCR analysis confirmed the predicted downregulation of CLEC14A and ROBO4 expression (Figure 9a ) in HUVEC exposed to 2 Pa of shear stress for 24 h. TIE1 is a validated marker of reduced shear stress at the endothelial surface (Chen-Konak et al., 2003; Porrat et al., 2004; Woo et al., 2011) . Double immunofluorescence staining of TIE1 and CLEC14A showed that they co-localised on tumor vessels (Figure 9b ). This provides further evidence that CLEC14A expression may be upregulated by low shear stress on tumor endothelium.
Discussion
One of the most significant findings of this work is that CLEC14A appears to be present at a markedly higher level on tumor endothelium compared with that in normal tissue. This was shown by both immunohistochemical and immunofluoresence analysis (Figures 2  and 3 ). The immunofluoresence study permitted CLE-C14A co-localization with the endothelial marker Ulex lectin, confirming endothelial expression of CLEC14A in vivo (Figure 3a) . It was further shown that CLEC14A mRNA expression was higher in endothelium isolated from hepatocellular carcinoma compared with that from healthy liver tissue. Expression of CLEC14A was substantial, and widespread across a range of solid tumors (Figure 3c ). Thus, expression was seen in all CLEC14A is a novel tumor endothelial marker M Mura et al ovarian and liver cancers, 90% of bladder and prostate and 80% of breast cancers. Of the common cancers, the only one in which CLEC14A showed poor expression was colorectal cancer. These results identify CLEC14A as a candidate for tumor vascular targeting. Figures 3c and d compare the expression of CLE-C14A and ROBO4 in the different cancers, and there are clear differences. For example, ROBO4 is expressed in lung but not CLEC14A, suggesting that multiple factors regulate their expression. Clearly, combined targeting could be useful in some tumors, whereas for lung cancer, ROBO4 would be more useful.
CLEC14A polarizes at the plasma membrane in the direction of cell migration and ectopic expression of CLEC14A increased filopodia formation in human embryonic kidney 293 and HeLa cell lines (Figures 4 Figure 5 Ectopic expression of CLEC14A induces filopodia formation. Human embryonic kidney 293 (HEK293; a) and HeLa (b) cells were transfected with CLEC14A-HA plasmid or empty plasmid (pCS2 þ -HA) and stained with anti-HA antibody and CellMask deep red plasma membrane stain. Note the formation of filopodia in CLEC14A-HA (upper panels in a and b) but not empty plasmid transfected cells (lower panels). DAPI, 4 0 ,6-diamidino-2-phenylindole.
CLEC14A is a novel tumor endothelial marker M Mura et al and 5). Knockdown of CLEC14A by siRNA disrupts endothelial migration and tube formation ( Figure 6 ). These data all support a role for CLEC14A in cell migration. A recent report described endothelial-specific expression of CLEC14A and its role in cell migration and tube formation (Rho et al., 2011) . Expression of CLEC14A in tumor vasculature suggests a role in pathological angiogenesis. To investigate a role in physiological angiogenesis, we used the zebrafish model of vascular development. In the zebrafish, clec14a expression coincides with the appearance of hemangioblasts and continues through later stages of development that involve angiogenesis. Previous work by others has shown that the transcription factor Etsrp appears to regulate expression of zclec14a to control vasculogenesis and primitive myelopoiesis Figure 6 SiRNA knockdown of CLEC14A identifies its role in endothelial cell migration and tube formation. (a) Western blot showing that two independent siRNA duplexes efficiently knockdown CLEC14A protein in HUVEC. b-Tubulin was used as a loading control. CLEC14A appears as two bands, the 100 kDa glycosylated mature protein and the 60 kDa unglycosylated precursor. (b) Immunofluorescence staining of CLEC14A showing its knockdown in HUVEC. Note that the CLEC14A siRNAs have no effect on VE cadherin expression, which was used to visualize the cell-to-cell contact region. (c-d) Scratch wound assay and (e-f) tube forming assay in HUVEC transfected with mock, scrambled or CLEC14A siRNA duplexes ( ± s.d
.). Graphical representation: solid black (0 h), open (12 h) and solid gray (24 h). DAPI, 4
0 ,6-diamidino-2-phenylindole.
CLEC14A is a novel tumor endothelial marker M Mura et al (Pham et al., 2007; Gomez et al., 2009 ). In addition, zclec14a (also known as C1qR-like gene) was previously identified as a putative endothelial-specific gene by microarray analysis of zebrafish cloche mutants that fail to undergo hematopoiesis (Sumanas et al., 2005) . At 24 h.p.f., zclec14a is expressed in endothelial cells and overlaps with endothelial marker zfli1a (Figure 8b ). Morpholino-mediated knockdown of zclec14a disrupted intersomitic and dorsal longitudinal anastomotic vessel formation, supporting a role for clec14a in vasculogenesis (Figure 8c ). The mouse ortholog of CLEC14A is also expressed in endothelial cells during development, suggesting an evolutionary conserved role for this protein in development of the vasculature (Rho et al., 2011) . Each gene expressed in a tumor will have a normal physiological function at some point in the life of an organism. CLEC14A is expressed in the embryonic vasculature but not the adult. CLEC14A expression in tumors shows that similar to carcinoembryonic antigen and a-fetoprotein, it is an example of an oncofetal antigen, but in the case of CLEC14A is vascular specific. CLEC14A is a member of the type 14 C-type lectin family that includes thrombomodullin, CD93 and endosialin/TEM1; all of which have a role in vascular biology. For example, thrombomodullin is expressed in endothelial cells and has anticoagulant activity resulting from sequestration of thrombin and activation of protein C (Maruyama et al., 1985; Esmon, 1995) . CD93 is expressed in endothelium, cells of myeloid lineage and stem cells (Bohlson et al., 2005) . Although not expressed by endothelium (MacFadyen et al., 2005) , TEM1/endosialin mediates tumor, but not developmental angiogenesis. Thus, orthotopically implanted colon tumors grow slower in the TEM1/endosialin À/À mouse, whereas developmental angiogenesis is normal (Nanda et al., 2006) . Endothelial-specific expression of CLE-C14A and functional studies now confirm a role for this type 14 C-type lectin family member in vascular biology.
Blood flow in tumor vessels compared with that in normal vessels is poor, sometimes static or even reversed (Gullino, 1975; Jain, 1988; Chaplin et al., 1997) . Poor blood flow leads to low shear stress at the endothelial surface. The mechanism by which endothelial cells sense shear stress and disturbed blood flow is much debated but may involve ion channels, adhesion proteins or endothelial cilia as mechanosensors (Ando and Yamamoto, 2009 CLEC14A is a novel tumor endothelial marker M Mura et al Topper, 2004; Matharu et al., 2008) . Around 3% of genes expressed in endothelial cells appear to be regulated by shear stress (Chu and Peters, 2008) . These include genes involved in cell proliferation, cell-adhesion, adenosine triphosphate synthesis, remodeling of the extracellular matrix and angiogenesis. Our data are consistent with low shear stress at the tumor endothelial surface being at least one of the factors leading to expression of CLEC14A and ROBO4 on tumor vessels.
CLEC14A is functionally involved in filopodia formation, cell migration and tube formation. Both CLEC14A and ROBO4 mediate endothelial migration in angiogenesis, and the ability to specifically block tumor endothelial cell migration could lead to novel anticancer approaches. Inhibition of endothelial cell migration and tube formation by CLEC14A antiserum suggests that migration-blocking monoclonal antibodies to CLEC14A may have therapeutic potential.
Materials and methods

Cell isolation and culture
Human aortic smooth muscle cells, human dermal microvascular endothelial cells and human bronchial epithelial cells were purchased from TCS Cellworks (Buckingham, UK). Human umbilical cords were dissected from placentas and the vein washed in sterile phosphate-buffered saline to remove blood. A volume of 1 mg/ml of collagenase type 1 A (Sigma, Gillingham, UK) diluted in M199 medium (Sigma) was injected into the vein and then incubated at 37 1C for 20 min to detach the endothelial cells. HUVECs were collected by washing in M199 complete medium containing 10% fetal calf serum, 10% large vessel endothelial cell growth supplement (TCS Cellworks) and 4 mM L-glutamine and then seeded on 0.1% type 1 gelatin from porcine skin (Sigma) coated plates. For flow experiments, HUVECs were cultured under static conditions for 24 h, and then exposed to shear stress of 2 Pa for 24 h. Paired static and flow microslides were exposed to identical recirculated medium for the same periods following previously described methods (Sheikh et al., 2004) . /196) . Tissues were weighed and minced. Tissue was then digested for 1.5 h with Dulbecco's modified Eagle's medium media containing 2 mg/ml collagenase type V (Sigma), 7.4 mg/ml of actinomycin (Sigma) and 30 kU/ml of DNAse I (Qiagen, Crawley, UK) at 37 1C on a shaker. Streptavidin-coated Dynabeads (Invitrogen, Paisley, UK) were incubated with 20 mg/ ml of Biotinylated Ulex lectin (Vector Labs, Burlingame, CA, USA) for 30 min at 37 1C on a shaker. The digested cell suspension was filtered through a 70 mm cell strainer following three washes with cold Dulbecco's modified Eagle's medium. Endothelial cells were then isolated by positive selection using Ulex coated beads and a magnet. Total RNA isolation was performed using RNeasy Mini kit (Qiagen).
Isolation of endothelial cells from healthy and tumor tissue
RNA extraction and real-time PCR analysis RNA extraction, complementary DNA preparation and quantitative PCR were performed using LightCycler real time quantitative RT-PCR (Roche, Burgess Hill, UK) following previously described methods (Armstrong et al., 2008) . CLEC14A primers were forward 5 0 -CTGGGACCGAGGT GAGTG-3 0 and reverse 5 0 -CGCGATGCAAGTAACTGA GA-3 0 with universal probe number 24. ROBO4 primers were forward 5 0 -CATCATCCGTGGCTACCAG-3 0 ; reverse 5 0 -CAGTTGGCTGGTGGCAGT-3 0 with universal probe number 61. Flotillin-2 primers were forward 5 0 -TGTTGTGG TTCCGACTATAAACAG-3 0 and reverse 5 0 -GGGCTGCAA CGTCATAATCT-3 0 with universal probe number 28. The fold change was calculated using the DDCt method.
Immunohistochemistry of paraffin-embedded tissue After paraffin was removed, sections were rehydrated and endogenous peroxidase blocked using 0.3% hydrogen peroxide in distilled water (15 min). Tissues were then subjected to an overnight low temperature epitope retrieval technique as previously described (Reynolds et al., 2002) . After mounting in a Shandon sequenzer, sections were treated with a 2% casein block (10 min) and then incubated with 10 mg/ml CLEC14A polyclonal antibody (R&D Systems, Abingdon, UK) in Tris-buffered saline (pH 7.6) for 1 h. Following a Tris-buffered saline- wash, sections were visualized using Vector ImmPRESS universal antibody kit (30 min) and Vector NovaRed chromagen (5 min; Vector Labs). Finally sections were counterstained with Mayers hematoxylin, dehydrated, cleared and mounted in distyrene-plasticizer-xylene resin. Slides were examined on a Nikon Eclipse E400 microscope (Nikon, Kingston upon Thames, UK) and images captured with a Nikon Coolpix 995 camera.
Immunofluorescence staining of paraffin-embedded tissue Tissue was obtained from the Cancer Research UK histology service (REC reference number 06/Q2707/338) or Super Biochips Inc. (Seoul, South Korea). Following paraffin removal, tissues were rehydrated and microwaved to boiling in citrate buffer (pH 6) to permit antigen retrieval. Sections were then blocked in phosphate-buffered saline-Tween-20 (0.1% vol/vol) containing 10% fetal calf serum and 3% bovine serum albumin. Sections were probed with 10 mg/ml of anti-CLEC14A antibody (R&D Systems) and 15 mg/ml of fluorescein isothiocyanate-conjugated rabbit immunoglobulin G (IgG) secondary anti-sheep polyclonal antibody (Invitrogen). Endothelial cells were visualized with 20 mg/ml of Ulex lectin conjugated to rhodamine (Vector Labs). For TIE1 staining, 5 mg/ml of anti-TIE1 antibody (Abcam) was applied to sections followed by 15 mg/ml of Alexa Fluor 546 goat anti-rabbit IgG (Invitrogen). Slides were mounted with Prolong gold anti-fade reagent containing 4 0 ,6-diamidino-2-phenylindole (Invitrogen). Sections were examined using an Axiovert 100 M laser scanning confocal microscope (Carl Zeiss, Welwyn Garden City, UK).
Zebrafish mRNA in situ hybridization, RT-PCR and morpholino knockdown Zclec14a complementary DNA was amplified from 24 h.p.f. complementary DNA using forward 5 0 -GGAGAAAAAGCA GACAATATCATTTTA-3 0 and reverse 5 0 -AGTCTCTCT CACTTAGGTTTCCTCTTT-3 0 primers. The 1172 bp PCR fragment generated by these primers was cloned into pCRBlunt II-TOPO (Invitrogen) and sequenced. Digoxigeninlabeled sense and antisense RNA probes for in situ hybridization were generated by in vitro transcription using an RNA labeling kit (Roche). To generate the sense probe, the plasmid was linearized with KpnI and transcribed with T7 polymerase. Zclec14a antisense probe was generated by linearizing the plasmid with XhoI and transcribing with SP6. Zfli1a antisense probe was generated by linearizing the plasmid with Spe1 and transcribing using T7 polymerase. mRNA in situ hybridization was carried out following previously described methods (Thisse and Thisse, 2008) . Images were captured using a Nikon SMZ 800 microscope and Nikon DXM 1200 camera.
To analyze the temporal pattern of zclec14a expression, complementary DNA from various developmental stages of zebrafish was amplified using the following primers, forward 5 0 -AAACCTAAGTGAGAGAGACTGTGC-3 0 and reverse 5 0 -ACAGAGTACGCTATTTTCATCCATC-3 0 . Elongation factor-1a was used as a loading control, elongation factor-1a forward primer: 5 0 -CACCCTGGGAGTGAAACA-3 0 , elongation factor-1a reverse primer 5 0 -ACTTGCAGGCGATGTG AGC-3 0 . Two morpholino antisense oligonucleotides were provided by Gene Tools LLC (Philomath, OR, USA). The zclec14a morpholino 5 0 -ACCATCCAGAAATCCATGTCT GCTC-3 0 targets the translation start site and blocks protein translation. A standard negative morpholino control 5 0 -CCTCTTACCTCAGTTACAATTTATA-3 0 was also used.
CLEC14A is a novel tumor endothelial marker M Mura et al
Morpholino antisense oligonucleotides were injected into single cell zebrafish embryos in 1 nl of Danieau buffer using a Narishige microinjector (Narishige International Ltd, London, UK). In the rescue experiment, N-terminally hemagglutinin (HA)-tagged human CLEC14A mRNA was synthesized by linearizing the hCLEC14A-HA/pCS2 þ plasmid with NotI and transcribing with SP6 polymerase using the mMessage mMachine Kit (Ambion, Warrington, UK). Images were captured using a Nikon SMZ 1500 microscope and Nikon digital sight DS-Qi1mc camera. Zebrafish studies were approved by Home Office license PPL 40/3131.
Immunofluorescence staining of HUVEC HUVEC were grown in glass micro-well chambers (Nunc, Roskilde, Denmark), fixed in ice-cold methanol and stained with CLEC14A antiserum as described for paraffin-embedded tissues. Cells were co-stained with 5 mg/ml mouse monoclonal IgG antibody against human VE cadherin (BU9) or 25 mg/ml IgG1 AlexaFluor 647 mouse anti-human GM130 (BD Bioscience, Oxford, UK). Images were acquired using an Axiovert 100 M laser scanning confocal microscope (Carl Zeiss).
Transfection of CLEC14A-HA Two HA tags were inserted between amino acids 24 and 25 of CLEC14A to generate an N-terminally HA-tagged construct. The HA tag was inserted into the construct by generating a NheI and a HindIII site that introduced the following amino acids: ASYPYDVPDYASELYPYDVPDYAKL into CLE-C14A (the HA tag sequence is underlined). The construct was cloned into the BamHI and EcoRI sites of plasmid pCS2 þ . Human embryonic kidney and HeLa cells were then transfected using GeneJuice (Merck, Hoddesdon, UK). Cells were fixed in 4% paraformaldehyde (PFA) and stained with 3F10 (Roche) rat monoclonal anti-HA antibody and CellMask plasma membrane stain (Invitrogen).
Functional assay with siRNA knockdown and CLEC14A antiserum Transfection with siRNA and functional assays were performed as previously described (Armstrong et al., 2008) . CLEC14A siRNA duplexes were: D1-GAACAAGACAATT CAGTAA and D2-CAATCAGGGTCGACGAGAA (EuroGentec, Liege, Belgium). Alternatively, functional assays were performed using medium containing 5, 10 or 20 mg/ml of CLEC14A antiserum (R&D Systems) . The open area of the wound was quantified using a cell intelligence quotient analyzer or Image J software (Image J website, rsbweb.nih. gov). The branches emerging at 24 h from each node were counted in three different fields of the same well. Evaluation of the branches was assessed by their quality as follows: well developed branches, moderately developed branches and poorly developed branches. Images were acquired using a Leica DM IL microscope (Leica, Milton Keynes, UK) and USB 2.0 2M Xli camera (XL Imaging LLC, Carrollton, TX, USA).
Statistical analysis
Statistical analyses were carried out using the MedCalc software package (www.medcalc.com). One-way analysis of variance was used to analyze the effect of knockdown and antiserum. Student's t-test was used for the pair-wise comparison of different groups.
